Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Insmed with a target price of $162. In a cautious move, an analyst from Barclays downgraded its rating to …
4INSM : A Closer Look at Insmed’s Options Market Dynamics
view original post